Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 313.8 Million EUR | 42.02% |
| 2022 | 220.95 Million EUR | 22.5% |
| 2021 | 180.36 Million EUR | 109.96% |
| 2020 | 85.9 Million EUR | 455.27% |
| 2019 | 15.47 Million EUR | 129.61% |
| 2018 | 6.73 Million EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 240.12 Million EUR | 38.15% |
| 2024 Q2 | 182 Million EUR | -41.69% |
| 2024 Q1 | 312.12 Million EUR | -0.53% |
| 2023 FY | 313.8 Million EUR | 42.02% |
| 2023 Q3 | 337.57 Million EUR | -0.42% |
| 2023 Q4 | 313.8 Million EUR | -7.04% |
| 2023 Q2 | 339 Million EUR | 42.21% |
| 2023 Q1 | 238.37 Million EUR | 7.88% |
| 2022 Q4 | 220.95 Million EUR | -25.55% |
| 2022 FY | 220.95 Million EUR | 22.5% |
| 2022 Q3 | 296.79 Million EUR | -5.95% |
| 2022 Q2 | 315.56 Million EUR | 6.0% |
| 2022 Q1 | 297.7 Million EUR | 65.06% |
| 2021 Q2 | 128.1 Million EUR | 49.43% |
| 2021 Q4 | 180.36 Million EUR | 39.55% |
| 2021 Q3 | 129.24 Million EUR | 0.89% |
| 2021 FY | 180.36 Million EUR | 109.96% |
| 2021 Q1 | 85.72 Million EUR | -0.21% |
| 2020 FY | 85.9 Million EUR | 455.27% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 85.9 Million EUR | 0.0% |
| 2019 FY | 15.47 Million EUR | 129.61% |
| 2018 FY | 6.73 Million EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AroCell AB (publ) | - SEK | -Infinity% |
| Devyser Diagnostics AB (publ) | 74.8 Million SEK | -319.52% |
| Immunovia AB (publ) | 4.28 Million SEK | -7221.535% |
| Prostatype Genomics AB (publ) | 67 Thousand SEK | -468259.701% |
| SenzaGen AB | 1.67 Million SEK | -18656.784% |
| Spermosens AB | 9.51 Million SEK | -3197.268% |